Europe
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
GW Pharmaceuticals hopes to bring its cannabis-based treatment nabiximols for multiple sclerosis spasticity to the United States.
Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.
Santhera said the restructuring will allow the company to focus on the development of vamorolone, a first-in-class dissociative steroid with a novel mode of action that it gained the rights to from ReveraGen BioPharma.
Kiadis has three compounds in the clinic: K-NK002 in Phase II for HSCT in blood cancer; K-NK003 for relapsed or refractory acute myeloid leukemia (AML); K-NK-ID101 for COVID-19.
A seroprevalance study of 15,591 children in Bavaria, published October 28th in Med, revealed a six-fold greater prevalence of the SARS-CoV-2 virus than reported cases.
Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
AstraZeneca is divesting two cardiovascular drugs to Germany’s Cheplapharm Arzneimittel GmbH for $400 million, which will allow the UK pharma giant to reinvest in its main therapy areas.
PRESS RELEASES